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Abstract
Background: Detectable HIV RNA in mothers at delivery is an important risk factor for HIV transmission to
newborns. Our hypothesis was that, in migrant women, the risk of detectable HIV RNA at delivery is greater owing
to late HIV diagnosis. Therefore, we examined pregnant women by regional provenance and measured variables
that could be associated with detectable HIV RNA at delivery.
Methods: A observational retrospective study was conducted from January 1999 to May 2008. Univariate and
multivariable regression analyses (generalized linear models) were used, with detectable HIV RNA at delivery as
dependent variable.
Results: The overall population comprised 154 women (46.8% migrants). Presentation was later in migrant women
than Italians, as assessed by CD4-T-cell count at first contact (mean 417/mm
3 versus 545/mm
3, respectively; p =
0.003). Likewise, HIV diagnosis was made before pregnancy and HAART was already prescribed at the time of
pregnancy in more Italians (91% and 75%, respectively) than migrants (61% and 42.8%, respectively). A subgroup of
women with available HIV RNA close to term (i.e., ≤30 days before labour) was studied for risk factors of detectable
HIV RNA (≥50 copies/ml) at delivery. Among 93 women, 25 (26.9%) had detectable HIV RNA. A trend toward an
association between non-Italian nationality and detectable HIV RNA at delivery was demonstrated by univariate
analysis (relative risk, RR = 1.86; p = 0.099). However, by multivariable regression analysis, the following factors
appeared to be more important: lack of stable (i.e., ≥14 days) antiretroviral therapy at the time of HIV RNA testing
(RR = 4.3; p < 0.0001), and higher CD4+ T-cell count at pregnancy (per 50/mm
3, RR = 0.94; p = 0.038).
Conclusions: These results reinforce the importance of extensive screening for HIV infection, earlier initiation of
antiretroviral therapy and stricter monitoring of pregnant women to reduce the risk of detectable HIV RNA at
delivery. Public health interventions should be particularly targeted to migrant women who are frequently unaware
of their HIV status at the time of pregnancy.
Background
UNAIDS estimated that 31.3 million patients lived with
HIV infection worldwide in 2008; among them, 15.7
million were women [1]. Before the introduction of
combination antiretroviral therapy (cART), about 25% of
infants born to HIV-infected women became HIV
infected, but this risk was reduced by cART [1]. As a
consequence, many women desire to have children
despite HIV infection, while others become pregnant
unaware that they are infected with HIV. For instance,
more than 6,000 women living with HIV become preg-
nant in the United States every year [2].
Detectable HIV RNA at delivery is the strongest pre-
dictor of mother-to-child HIV transmission [3]. Katz
et al. [4] examined the association between cART,
demographic factors and detectable HIV-RNA at deliv-
ery. Alarmingly, 32% of the women displayed detectable
HIV RNA at delivery, which was significantly associated
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pregnancy, but not type of cART [4]. A recent study of
the European Collaborative Cohort highlighted a group
of pregnant women with detectable HIV RNA at deliv-
ery notwithstanding cART, suggesting the importance of
strict monitoring and support for HIV-infected pregnant
women [5].
In Italy, characteristics of HIV-infected pregnant
women and possible determinants of positive HIV RNA
at delivery have been poorly studied [6]. In particular,
maternal characteristics of migrants in comparison to
autochthonous populations and the possible impact of
m i g r a t i o no nt h er i s ko fp o s i t i v eH I VR N Aa td e l i v e r y
have not yet been investigated. We hypothesized that
HIV infection is diagnosed in migrants later than in Ita-
lians, with consequences for the risk of detectable HIV
RNA at delivery. First, we compared maternal character-
istics of Italian and non-Italian women to determine
whether there were any differences in terms of timing of
presentation and cART initiation; second, we selected
the women for whom HIV RNA close to term was avail-
able to explore possible risk factors for detectable HIV
RNA at delivery, including patient nationality.
Methods
Characterisation of the overall population by
geographical origin and management of pregnant
women and newborns
A retrospective study was conducted on all pregnant
women attending a large outpatient HIV clinic in
Brescia (northern Italy) from January 1999 to July 2008.
Pregnant women were initially referred to our clinic by
general practitioners, obstetric services and services for
sexually transmitted diseases at the time of HIV diagno-
sis, or were already on follow-up when they were found
to be pregnant. On the basis of Italian guidelines for
antiretroviral therapy available at the time of the study
[7], the women were followed during pregnancy with
examinations and clinical examinations every three
months, using an integrated approach (HIV disease
management and obstetric evaluation). Complete blood
tests (including CD4+ T-cell count and HIV RNA) were
performed, and the women were screened for latent
tuberculosis infection, TORCH (T. gondii,o t h e r s ,
Rubella, Cytomegalovirus, HIV) and malaria, if clinically
indicated. HIV RNA was determined by branched DNA
quantification (Bayer bDNA test, Versant HIV-1 RNA
3.0 assay [bDNA], Bayer Health Care). Antiretroviral
treatment was commenced as soon as possible if indi-
cated by the mothers’ conditions [7]; otherwise, cART
was initiated as soon as the mothers entered the 2
nd tri-
mester of pregnancy. Italian guidelines edited in 2005
recommended beginning antiretroviral therapy at CD4+
T-cell count ≤350 cells/mm
3; treatment at 350 < CD4+
< 500 cells/mm
3 was only suggested if HIV RNA was
>100,000 copies/ml [7]. HIV-infected women were deliv-
ered by caesarean section, and zidovudine was infused
as prophylaxis during delivery. Breastfeeding was
discouraged.
The children were followed at the Paediatric Clinic of
the local hospital (Spedali Civili di Brescia) with clinical
evaluation and complete blood tests including HIV anti-
body test (ELISA) and HIV RNA on day 0, week 4,
week 8, week 24, week 48 and week 96. Children were
considered to be negative for HIV infection if HIV RNA
and HIV antibody tests were negative at week 48.
This study was approved by the Ethical Committee of
the Spedali Civili di Brescia. The patients signed the
informed consent for participation to this study.
Factors associated with detectable HIV RNA at delivery
(subgroup of mothers with available HIV RNA close to
term)
For this analysis, we considered only patients with avail-
able HIV RNA measured close to term (i.e., ≤30 days
before delivery). Log-normal generalized linear regres-
sion models were used to assess factors associated with
the outcome, defined as detectable HIV RNA (i.e., ≥50
copies/ml) close to term. Variables were selected on the
basis of plausibility of their association with the out-
come and epidemiological relevance, and to avoid possi-
ble biases. For example, CD4+ T-cell counts at delivery
were not included, since antiretroviral therapy and time
of initiation were likely to influence these values and
HIV RNA at the same time. Therefore, the following
variables were selected: geographical provenance (Italy
versus other countries), age, calendar year at pregnancy,
CD4+ T-cell count at pregnancy, and presence/type of
cART at the time of HIV RNA testing (no therapy ver-
sus two antiretroviral drugs versus at least three drugs
in combination, i.e., HAART regimens). Therapy was
considered to be present if it was initiated at least
14 days before HIV RNA testing.
Since the 9 patients who were not prescribed cART at
pregnancy were the same who were not on cART close
to term, in the multivariable model we used a single
dichotomy variable (no cART versus any cART close to
term). Moreover, since all these 9 patients were non-Ita-
lians, there was an effect modification between country
of origin and treatment exposure. For this reason,
nationality was excluded from the main multivariable
model. Lastly, in order to test whether nationality was
correlated with detectable HIV RNA close to term, the
9 patients without treatment were excluded from a mul-
tivariable model that included nationality as variable.
Risk ratios (RR) with corresponding 95% confidence
intervals were used to describe the strength of the
associations.
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The time of diagnosis of HIV infection was at the first
positive HIV confirmatory test (western blotting), and
the CD4+ T-cell count and HIV RNA at diagnosis were
the first values obtained after HIV diagnosis. The time
of pregnancy diagnosis was considered to be the last
menstrual period, and CD4+ T-cell count and HIV
RNA at pregnancy were the first values obtained after
pregnancy diagnosis. Lastly, cART at delivery was the
regimen at the last blood test before delivery.
The chi square test and score test for trend were used
when appropriate. All statistical tests were two sided.
P-values <0.05 were considered to be significant. Data
were collected in an electronic chart used in our Centre
(NetCare, version 1.05.11 sp 26) and double-checked for
consistency and completeness with paper charts. Statisti-
cal analyses were performed using STATA software
(Stata Statistical Software release 9.2, 2007; Stata
Corporation, College Station, Texas).
Results
Characteristics of the population by geographical origin
One hundred and fifty-four pregnant women were
included in the study (table 1). Most of the patients
(46.7%) came from Italy or from Africa (42.4%), the
remainder from Eastern Europe (6.3%) or from different
countries (4.5%). The non-Italian patients had acquired
HIV through heterosexual intercourse more frequently
(p < 0.0001), and had received HIV diagnosis later (p <
0.0001) and during pregnancy (p < 0.0001), than the Ita-
lians. Two Italian women were infected vertically. More-
over, non-Italians had more previous pregnancies
(p = 0.078), and presented with lower CD4+ T-cell count
(p = 0.003), than Italians. Conversely, Italians were pre-
scribed cART earlier than the non-Italians (p = 0.006).
Figure 1 depicts the flow of patients. Thirteen women
had voluntary interruptions of pregnancy, 12 had spon-
taneous abortions, one had therapeutic abortion, and
three were lost to follow-up soon after the first contact
with the Centre. Therefore 125 women delivered. None
of the children acquired HIV infection in this cohort.
Factors associated with detectable HIV RNA at delivery
Among the 125 women who delivered, 93 had HIV
RNA determination close to term (i.e., ≤ 30 days before
delivery). Characteristics of these 93 women are illu-
strated in table 1. Moreover, CD4+ T-cell counts at
delivery were slightly lower among non-Italians (mean:
464.7/mm
3, SD 228.6/mm
3) than Italians (mean: 582.1/
mm
3, SD 237.7/mm
3) in the subset of patients with
available HIV RNA determination close to term (p =
0.018). Significant differences were found between the
93 women with HIV RNA determination close to term
and the remaining 61 women who lacked HIV RNA for
CD4+ T-cell count at first contact (mean: 439.1 cell/
mm
3,SD 253.7/mm
3 versus 535.7 cell/mm
3,S D2 9 8 . 2 /
mm
3; p = 0.032) and initiation of cART before preg-
nancy (80.3% versus 54.8%, p = 0.014). No significant
differences were found for the other variables between
the two groups.
Factors considered for association with detectable HIV
RNA at delivery and linear regression analysis are
s h o w ni nt a b l e2 .A m o n gt h e9 3w o m e nw i t ha v a i l a b l e
HIV RNA at delivery, 32/39 (82.0%) of the Italians ver-
sus 36/54 (66.7%) of the non-Italians had undetectable
HIV RNA at delivery. Therefore, by univariate linear
regression analysis, non-Italians had RR = 1.86 for
detectable HIV RNA at delivery with respect to the
Italians (p = 0.099). Age and calendar year were not sta-
tistically associated with the outcome.
Among nine patients who were not on cART for ≥14
days at the time of HIV RNA testing, only one (11%) had
undetectable HIV RNA. By contrast, among 78 patients
who were on ≥3 antiretroviral drugs, 61 (78%) had unde-
tectable HIV RNA and this percentage was not statistically
different from the percentage of patients with undetectable
HIV RNA among those who were prescribed two antire-
troviral drugs (6/6 = 100%). Therefore, by univariate analy-
sis, the RR of detectable HIV RNA was 4.4 (p < 0.0001) for
lack of cART versus any cART at the time of HIV RNA
testing. Similar results were obtained for presence/timing
of initiation of cART, resulting in an identical RR of
detectable HIV RNA for lack of cART versus any cART
initiated before or during pregnancy.
Lastly, increasing CD4+ T-cell count at pregnancy
appeared to reduce the risk of detectable HIV RNA at
delivery by univariate analysis (RR = 0.91 per 50 cells/
mm
3; p = 0.037). All continuous variables included in
the regression model were also studied as categorical
variables to confirm the linear relationship; in particular,
upper classes of CD4+ T-cell counts (200-349; 350-499;
>500/mm
3) were associated with a lower risk of detect-
able HIV RNA at delivery with respect to CD4+ <200/
mm
3 (data not shown).
Multivariable analysis confirmed that the risk of
detectable HIV-RNA at delivery was increased by lack
of cART, while higher CD4+ T-cell count at the begin-
ning of pregnancy appeared to be protective; by con-
trast, age and calendar year did not appear to be
associated with HIV-RNA at delivery (see Table 2).
After excluding from the analysis the 9 patients who
were not receiving any cART, we found that nationality
was not independently associated with the risk of detect-
able HIV RNA close to term (RR = 0.91; p = 0.8). Also,
in this model, results for the other variables did not
change significantly. In particular, the protective role of
CD4+ T-cell count at pregnancy was confirmed (risk
ratio = 0.87 per 50 cells/mm
3; p = 0.049).
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Pregnant women (all) Pregnant women (HIV RNA available within 30 days
before delivery)
Characteristic N Italians Non-Italians p N Italians Non-Italians p
Age (mean years, SD) 154 33.7 (6.2) 29.8 (4.9) <0.0001 93 32.8 (6) 30 (4.4) 0.004
Risk factor for HIV infection (N, %) 154 93
Heterosexual intercourse 39 (54.2) 69 (84.1) 22 (56.4) 46 (85.2)
IVDU 29 (40.2) 2 (2.4) 13 (33.3) 0
Mother-to-child 2 (2.8) 0 2 (5.1) 0
Parenteral 0 3 (3.7) 0 3 (5.6)
Unknown 2 (2.8) 8 (9.8) <0.0001 2 (5.1) 5 (9.3) <0.0001
Calendar year at HIV diagnosis (N, %) 144 86
≤1990 16 (23.9) 2 (2.6) 9 (25.7) 1 (2)
1991-1995 19 (28.4) 1 (1.3) 10 (28.6) 1 (2)
1996-2000 7 (10.4) 15 (19.5) 3 (8.6) 7 (13.7)
2001-2005 20 (29.8) 42 (54.5) 10 (28.6) 28 (54.9)
≥2006 5 (7.5) 17 (22.1) <0.0001 3 (8.6) 14 (27.4) <0.0001
Calendar year at pregnancy (N, %) 154 93
1999 0 1 (1.2) 0 0
2000 0 0 0 0
2001 0 1 (1.2) 0 0
2002 1 (1.4) 2 (2.4) 1 (2.6) 2 (3.7)
2003 9 (12.5) 6 (7.3) 2 (5.1) 2 (3.7)
2004 12 (16.7) 12 (14.6) 8 (20.5) 5 (9.3)
2005 15 (20.9) 14 (17.1) 7 (18) 11 (20.4)
2006 14 (19.4) 18 (22) 8 (20.5) 14 (26.9)
2007 15 (20.8) 21 (25.6) 8 (20.5) 15 (27.8)
2008 (January-July) 6 (8.3) 7 (8.6) 0.865 5 (12.9) 5 (9.3) 0.764
Previous pregnancies (mean, SD) 121 0.9 (1.1) 1.5 (1.7) 0.078 72 0.8 (0.7) 1.5 (1.5) 0.102
HIV diagnosis related to this pregnancy (N, %) 144 86
Previous 61 (91.0) 47 (61.0) 32 (91.4) 29 (56.9)
During pregnancy 6 (9.0) 30 (39.0) <0.0001 3 (8.6) 22 (43.1) 0.001
Pregnancy outcome (N, %) 154 93
Delivery 55 (76.4) 70 (85.4) 39 (100) 54 (100)
Voluntary abortion 9 (12.5) 4 (4.9)
Spontaneous abortion 5 (6.9) 7 (8.5)
Therapeutic abortion 1 (1.4) 0
Unknown 2 (2.8) 1 (1.2) 0.445 N.A.
CD4+/mm
3 at first contact (mean, SD) 154 545.6 (281.5) 417.5 (256.8) 0.003 93 495.1 (273.1) 398.7 (232.9) 0.070
CD4+/mm
3 at first contact (N, %) 154 93
<200 2 (2.8) 12 (14.7) 2 (5.1) 9 (16.7)
200-349 20 (27.8) 32 (39) 13 (33.3) 21 (38.9)
350-499 18 (25) 16 (19.5) 10 (25.7) 11 (20.4)
≥500 32 (44.4) 22 (26.8) 0.010 14 (35.9) 13 (24) 0.250
CD4+/mm
3 at pregnancy (mean, SD) 151 485.6 (247.3) 429.6 (252.9) 0.171 93 488 (222.1) 411 (217.2) 0.095
CD4+/mm
3 at pregnancy (N, %) 151 93
<200 6 (8.3) 12 (15.2) 2 (5.1) 9 (17)
200-349 19 (26.4) 27 (34.2) 12 (30.8) 18 (33.3)
350-499 16 (22.2) 13 (16.4) 6 (15.4) 9 (16.7)
≥500 31 (43.1) 27 (34.2) 0.300 19 (48.7) 18 (33.3) 0.265
Timing of antiretroviral therapy initiation (N, %) 125 93
Before pregnancy 41 (74.5) 30 (42.8) 28 (71.8) 23 (42.6)
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Increasing numbers of HIV-infected women are becoming
pregnant or are planning a pregnancy owing to the wide-
spread use of cART and a decrease in HIV-related mortal-
ity and morbidity in developed countries [8]. In our HIV
cohort we included 154 pregnant women from January
1999 to July 2008. More than half of them were migrants
(especially from Africa), reflecting the burden of immigra-
tion in Italy in recent years [6,9]. Importantly, more than
one quarter of the migrants were diagnosed with HIV at
the time of pregnancy, underlining the fact that HIV
would have been diagnosed before pregnancy if the
screening policy were more extensively implemented, thus
allowing cART to be initiated earlier, in line with current
recommendations [2]. Indeed, current Italian guidelines
suggest treatment irrespective of CD4+ count in case of
pregnancy. At the same time, this finding indicates that
pregnancy offers a unique opportunity for HIV screening,
especially in high-risk populations of migrant women.
Likewise, CD4+ T-cell counts at the first contact with
our clinic were significantly lower among non-Italian
women than Italians, reflecting more advanced stages of
HIV infection and a later HIV diagnosis in the former.
Furthermore, CD4+ T-cell counts at delivery were lower in
the subset of non-Italian patients with available HIV RNA
at delivery. It has already been demonstrated that lower
CD4+ T-cell count at delivery is a risk factor for mother-
to-child transmission of HIV [10]. Once again, these con-
siderations reinforce the need for earlier diagnosis and
treatment of HIV infection, particularly in migrant women.
It is important to note that, in about one quarter (31/
125) of the women who delivered, HIV RNA was not
measured in the 30 days before delivery, making it
impossible to identify the risk of transmission to the
newborn, suggesting appropriate interventions (e.g.,
treatment change or intensification, therapeutic drug
monitoring to confirm low adherence and/or poor drug
bioavailability, modification of drug dosage or counsel-
ling to improve adherence). The Italian guidelines for
antiretroviral therapy edited in 2005 [7] suggested simi-
lar schedules of follow-up for pregnant women and for
the other patients (every 2-3 months). The lack of HIV
RNA determination close to term was due to the fact
that 26/61 (42.6%) women had abortions and 3/61 were
lost to follow-up. Furthermore, the lack of HIV RNA
determination in the remaining 32/61 (52.5%) women
was due to compliance with the previous guidelines,
which suggested an infrequent schedule of monitoring
rather than lack of patient adherence to the scheduled
follow-up. Although none of the mothers transmitted
the infection, such infrequent follow-up constituted a
potential risk just because HIV RNA was not deter-
mined, so the risk was not identified and appropriately
addressed. In view these considerations, the most recent
Italian guidelines for antiretroviral treatment [11] has
suggested that the follow-up of pregnant women should
be stricter, at least in those who have started or modi-
fied cART during pregnancy. Moreover, further HIV
RNA determinations are now recommended between
the 34
th and the 36
th weeks of gestation [11]. Our find-
ings support these recommendations.
In 25/93 (26.9%) women in whom HIV RNA was
tested close to term, detectable HIV RNA values were
found. Percentages of detectable HIV RNA at delivery
were even greater in previous studies [4,5], highlighting
the importance of studies on risk factors for detectable
HIV RNA at delivery to optimize the clinical manage-
ment of HIV in pregnant women.
Table 1 Characteristics of the cohort (overall and sub-study population) (Continued)
1
st trimester 4 (7.3) 7 (10) 3 (7.7) 7 (13)
2
nd trimester 8 (14.5) 19 (27.1) 7(18) 12 (22.2)
3
rd trimester 1 (1.8) 5 (7.1) 1 (2.6) 4 (7.4)
No therapy 1 (1.8) 9 (12.9) 0.006 0 8 (14.8) 0.026
Type of antiretroviral therapy at delivery; N (%) 125 93
2 NRTIs 2 (3.6) 4 (5.7) 1 (2.6) 3 (5.6)
3 NRTIs 1 (1.8) 0 1 (2.6) 1 (1.6)
2 NRTIs + NNRTI 18 (32.7) 23 (32.9) 12 (30.8) 15 (27.8)
2 NRTIs + PI 30 (54.5) 27 (38.6) 24 (61.5) 24 (44.4)
Other regimens 4 (7.2) 3 (4.2) 1 (2.6) 1 (1.6)
No cART 0 13 (8.6) 0.065 0 10 (18.5) 0.170
Type of antiretroviral therapy at delivery; N (%) 125 93
No cART 0 13 (18.6) 0 10 (18.5)
2 drugs 3 (5.4) 6 (8.6) 2 (5.1) 4 (7.4)
≥3 drugs 52 (94.6) 51 (72.8) 37 (94.9) 40 (74.1) 0.014
N: the number of data available for the characteristics considered. IDVU: intravenous drug users; SD: standard deviation; NRTIs: nucleoside/nucleotide reverse
transcriptase inhibitors; NNRTIs: non nucleoside/nucleotide reverse transcriptase inhibitors; PIs: protease inhibitors; cART: combination antiretroviral therapy; N.A.:
not applicable.
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a statistically significant association was found between
risk of detectable HIV RNA at delivery and lower CD4+
T-cell count at pregnancy onset. This finding is not new
since it was previously demonstrated by Katz et al. [4],
indicating that initiation of cART when the immune sys-
tem is less compromised could help reduce HIV RNA to
undetectable levels at delivery. Interestingly, type of
cART (dual or triple therapy) did not appear to influence
the risk of detectable HIV RNA at delivery, while any
cART had a significant protective effect, even though it
was initiated during later stages of pregnancy. This find-
ing is reassuring because it suggests that cART has a pro-
tective effect even though it is initiated late in pregnancy,
but only in cases where earlier treatment is not feasible
owing to late diagnosis of HIV infection. Indeed, our
results must be interpreted with caution and must not be
used to conclude that cART can be initiated later and
with suboptimal regimens. In fact, dual therapy is not
recommended [7]. Moreover, our sample size was extre-
mely small for some categories (only six patients were
treated with dual cART and only five started cART in the
third trimester). Clearly, a larger number of patients
might have altered the results.
 
154 HIV pregnant women 
Included in the study of the 
maternal characteristics 
125 deliveries 
Abortions 
  13 voluntary 
  13 spontaneous   
                          or   
                 therapeutical 
3 lost to follow-up 
93 women with HIV RNA 
determined between 0 and 30 
days before delivery 
Included in the study of  
predictors of positive 
HIV RNA at delivery 
Women with HIV RNA 
determined >30 days 
before delivery 
  19 between 31        
                and 60 days 
  12 >60 days 
1 lost to follow-up 
Figure 1 Flow chart of the patients included in the study.
Table 2 Univariate and multivariable regression analyses
Patient characteristics N = 93 Risk ratio for detectable HIV-RNA at delivery
(95% confidence interval); p-value
Patients with undetectable
HIV-RNA at delivery N = 68
Patients with detectable
HIV-RNA at delivery N = 25
Univariate analyses Multivariable regression analyses
using generalized linear models
Nationality (N, %)
Italian 32/39 (82.1%) 7/39 (17.9%) Ref. Excluded due to collinearity with
cART
Non-Italian 36/54 (66.7%) 18/54 (33.3%) 1.86 (0.86- 4.01);
p = 0.099
Age (mean
years, SD)
31.5 (5.5) 30.5 (4.99) For each year 0.98
(0.93-1.04); p = 0.5
For each year 0.99 (0.94-1.05); p =
0.9
Calendar year at
pregnancy
(mean, SD)
2005.8 (1.6) 2005.6 (1.3) For each year 0.93
(0.76-1.15); p = 0.7
For each year 0.96 (0.85-1.10); p =
0.6
cART at HIV RNA
test (N, %)
0 drugs 1/9 (11%) 8/9 (89%) 4.4 (2.7-7.1); p < 0.0001 Dichotomy variable (no cART -
versus- any cART)
2 drugs 6/6 (100%) 0/6 (0%)
≥3 drugs 61/78 (78%) 17/78 (22%) Ref. 2 or ≥3 drugs (no
differences among the 2)
4.4 (2.7-7.2) P < 0.0001
cART relative to
pregnancy (N, %)
before 2
nd
trimester
49/60 (82%) 11/60 (18%) Ref. any periods (no
differences among the 3)
2
nd trimester 14/19 (74%) 5/19 (26%)
3
rd trimester 4/5 (80%) 1/5 (20%)
No therapy 1/9 (11%) 8/9 (89%) 4.4 (2.7-7.1); P < 0.0001
CD4+/mm
3 at
pregnancy
(mean, SD)
468 (223) 376 (204) For each 50 CD4+/mm
3
0.91 (0.84-0.99); P = 0.037
For each 50 CD4+/mm
3 0.94 (0.89-
0.99); P = 0.032
Analyses were on patients with plasma viral load measured at the time of delivery (within 30 days before delivery). cART: combination antiretroviral therapy; Ref.:
reference category.
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effect of patient nationality on the risk of detectable
HIV RNA at delivery. There was only a trend toward a
statistically significant effect of non-Italian nationality by
univariate analysis, and this disappeared on multivariable
analysis. Once again, the small number of patients could
have influenced the results, but it is possible that beha-
vioural factors associated with nationality (i.e., late HIV
diagnosis and late initiation of cART) or other factors
not captured in this analysis (e.g., low patient adherence
or unmeasured characteristics of the virus such as HIV
drug resistance or viral subtype [12]) were more impor-
tant than nationality “per se”. Therefore our results sug-
gest that early diagnosis and treatment, though
prioritized in the migrants, should be extended to the
overall population. A screening campaign in the general
population and adherence to the recommendation to
test pregnant women for HIV are mandatory.
This study has several limitations that need to be
recognised. First, it was a retrospective analysis, so sev-
eral items of information were not recorded. In particu-
lar, because they were not available for the earliest
calendar years, HIV drug resistance testing, viral sub-
types or therapeutic drug monitoring results were not
considered. Second, as previously discussed, the sample
size was small. Third, HIV RNA was available at delivery
for only 93 women. Therefore, there should be further
investigation of maternal characteristics and pregnancy
outcomes in migrant and autochthonous women using
prospective cohorts with completed data and larger
sample size.
Conclusions
Overall our results reinforce the recommendation to
start HAART as soon as possible in pregnant women.
Clearly, this is only achievable by testing for HIV as
soon as possible. Migrant patients appeared to be a vul-
nerable population because they were more frequently
unaware of their HIV status at the time of pregnancy
than Italians. Since there is no nationwide legislation
that imposes HIV-testing in pregnant women in Italy,
our results have important public health implications.
Moreover, they indicate the need for a strict virological
and clinical follow-up of pregnant women to detect
amendable causes of positive HIV RNA at delivery to
minimize the risk of HIV transmission.
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